Literature DB >> 26710725

Regression of massive cardiac rhabdomyoma on everolimus therapy.

Steven G Hoshal1, Bennett P Samuel2, Jeffrey R Schneider2, Leena Mammen3, Joseph J Vettukattil2.   

Abstract

Cardiac rhabdomyoma is the primary feature of the genetic disease, tuberous sclerosis complex, the most common cardiac tumor diagnosed in neonates and infants. Spontaneous regression is observed in most cases, but these tumors may cause hemodynamic instability, arrhythmias or other complications. We describe the case of a critically ill neonate, resuscitated after cardiac arrest secondary to massive locally invasive cardiac rhabdomyoma, who was successfully treated with everolimus (mammalian target of rapamycin [mTOR] inhibitor). Rapid tumor regression was observed on echocardiography, but it was unlikely that it was confounded by the natural disease course of regression. The presented case suggests that mTOR inhibitors may play a significant role in the treatment of large cardiac rhabdomyomas in critically ill neonates.
© 2015 Japan Pediatric Society.

Entities:  

Keywords:  cardiac rhabdomyoma; echocardiography; everolimus; mammalian target of rapamycin inhibitor; tuberous sclerosis complex

Year:  2015        PMID: 26710725     DOI: 10.1111/ped.12816

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  6 in total

1.  Prenatal and Postnatal Diagnosis of Rhabdomyomas and Tuberous Sclerosis Complex by Ultrafast and Standard MRI.

Authors:  Ying Zhou; Su-Zhen Dong; Yu-Min Zhong; Ai-Min Sun
Journal:  Indian J Pediatr       Date:  2018-01-09       Impact factor: 1.967

Review 2.  Medical treatment of tuberous sclerosis-related epilepsy.

Authors:  Shimrit Uliel-Sibony; Veronika Chernuha; Hadas Meirson; Aviva Fattal-Valevski
Journal:  Childs Nerv Syst       Date:  2020-08-22       Impact factor: 1.475

3.  Regression of Neonatal Cardiac Rhabdomyoma in Two Months Through Low-Dose Everolimus Therapy: A Report of Three Cases.

Authors:  Jeng-Sheng Chang; Ping-Yun Chiou; Shu-Hui Yao; I-Ching Chou; Ching-Yuang Lin
Journal:  Pediatr Cardiol       Date:  2017-08-05       Impact factor: 1.655

Review 4.  Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex-A Systematic Review.

Authors:  Monika Sugalska; Anna Tomik; Sergiusz Jóźwiak; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2021-05-05       Impact factor: 3.390

5.  Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.

Authors:  Afshin Saffari; Ines Brösse; Adelheid Wiemer-Kruel; Bernd Wilken; Paula Kreuzaler; Andreas Hahn; Matthias K Bernhard; Cornelis M van Tilburg; Georg F Hoffmann; Matthias Gorenflo; Sven Hethey; Olaf Kaiser; Stefan Kölker; Robert Wagner; Olaf Witt; Andreas Merkenschlager; Andreas Möckel; Timo Roser; Jan-Ulrich Schlump; Antje Serfling; Juliane Spiegler; Till Milde; Andreas Ziegler; Steffen Syrbe
Journal:  Orphanet J Rare Dis       Date:  2019-05-03       Impact factor: 4.123

Review 6.  Cardiac Tumors: Diagnosis, Prognosis, and Treatment.

Authors:  Rossana Bussani; Matteo Castrichini; Luca Restivo; Enrico Fabris; Aldostefano Porcari; Federico Ferro; Alberto Pivetta; Renata Korcova; Chiara Cappelletto; Paolo Manca; Vincenzo Nuzzi; Riccardo Bessi; Linda Pagura; Laura Massa; Gianfranco Sinagra
Journal:  Curr Cardiol Rep       Date:  2020-10-10       Impact factor: 2.931

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.